探讨Tudor-SN蛋白参与调控软骨内成骨的作用与机制
批准号:
32070724
项目类别:
面上项目
资助金额:
58.0 万元
负责人:
杨洁
依托单位:
学科分类:
细胞命运及重编程
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
杨洁
中文摘要
本课题组多年来对Tudor-SN蛋白进行了系统研究,已成功构建Tudor-SN基因敲除(KO)小鼠,发现KO小鼠出生时呈现软骨发育不全和原发骨质疏松现象,提示Tudor-SN在软骨内成骨过程中发挥重要作用。软骨内成骨经历软骨细胞的增殖、分化和衰老等复杂过程,错综复杂的调控通路和分子机制备受关注。基于大量工作基础,本课题从几个层次进行探讨:Tudor-SN:Tudor-SN通过调控成骨关键因子Runx2和β-Catenin的蛋白水平,促进BMSC的分化能力;Tudor-SN通过与调控软骨细胞增殖的关键转录因子 Sox9共同作用;亦或作为新的TOP基因,通过mTOR通路调控另一软骨细胞增殖与分化的关键因子IHH活性,参与调控软骨内成骨。利用软骨细胞cKO小鼠,明确Tudor-SN缺失导致骨发育和骨内分泌功能异常,对靶器官功能的影响。本研究成果将为揭示原发性骨质疏松的发病机制提供理论依据。
英文摘要
The Tudor staphylococcal nuclease (Tudor-SN) protein is a multifunctional protein that involved in a variety of cellular processes, such as gene transcription, pre-mRNA splicing, DNA damage response and stress granule assembly. We have been focusing on investigating the physiologic function of Tudor-SN for nearly 10 years. We previously identified Tudor-SN as a novel regulator taking part in cell cycle regulation, and its expression level is closely related to the cell proliferation capacity that is highly expressed in proliferating cells while very low or undetectable in terminally differentiated cells. To further illustrate the n vivo function of Tudor-SN, we have successfully constructed Tudor-SN gene knockout mice (KO). The KO mice were born with cartilage dysplasia and primary osteoporosis. Comparing with the wild type mice, the bone density was significantly lower, the number of bone girders was significantly reduced, and the thickness of the cortical bone was very thin. All these suggest that Tudor-SN deficiency affected bone development in mice. The endochondral ossification forms most of the skeleton, including vertebrae, ribs and long bones. It involves an initial cartilage anlagen within which chondrocytes undergo an elaborate and well-controlled differentiation process. We therefore, hypothesize that Tudor-SN protein plays essential roles in endochondral ossificition. .Our research goal is to investigate the fundamental function of Tudor-SN in endochondral ossificition by regulating chondrocyte proliferation and differentiation. Linear growth is largely a function of endochondral bone elongation. It is accounted for by the complex regulation of chondrocyte proliferation, differentiation and senescence. The mesenchymal precursors first condense and commit to chondrocyte lineage under master regulator Sox9, Ihh by coordinating chondrocyte proliferation and differentiation. Runx2 and β-Catenin are essential factors for osteoblast. We revealed that in the bone tissue of new born KO-mice, the expression of Runx2 and β-Catenin was significantly lower than the WT-mice. In addition, using Data Base of Transcription Start Sites (DBTSS), we revealed that Tudor-SN is a terminal oligo-pyrimidine (TOP) gene. And we further confirmed the translation efficiency of Tudor-SN was controlled by mammalian target of rapamycin complex1 (mTORC1) pathway by using Torin 1 to inhibit the activated mTORC1 pathway cells. .All these observations prompted us to speculate that Tudor-SN plays essential roles in regulating chondrocyte proliferation and differentiation in endochondral ossificition. Aim 1: To determine the molecular mechanism by which Tudor-SN regulates the expression of Runx2 and β-Catenin in in the differentiation of BMSC to chondrocyte and osteoblast; Aim2: To characterize the function of Tudor-SN in collaborating with transcription factor Sox9 in regulating chondrocyte proliferation and differentiation; Aim3: To determine the involvement of Tudor-SN, as a new TOP gene, in regulating The Indian Hedgehog (IHH) activation through the mTOR signaling pathway; Aim4:To define the impact of Tudor-SN on primary osteoporosis, as well as secondary bone endocrine dysfunction and the consequence effect on the function of other target organs. The experiments will be carried out by using the conditional mice (cKO) with knockout of Tudor-SN gene in chondrocyte. .Significances: The goal of this study is to provide molecular insights and determine the important roles by which Tudor-SN regulates chondrocyte proliferation and differentiation. It may provide novel insights into the therapeutic strategies for primary osteoporosis.
成骨对于个体发育极其重要,它是一个复杂且受到精细调控的过程。成骨的不足会导致很多种疾病和发育的异常,甚至个体的死亡。然而成骨过程还有很多未解之谜。在此,我们发现多功能蛋白Tudor-SN可以参与软骨内成骨。当Tudor-SN缺失时,小鼠骨架变小,骨量减少,骨密度降低,骨小梁数量也随之减少,表现出成骨不全的表型。.在生长板中,主要包括四类软骨细胞,包括静息软骨,增殖软骨,前肥大软骨和肥大软骨。因此,我们利用特异性的基因来注释这四类软骨细胞。在静息软骨细胞的中,其标记基因Ucma,Mest和Frzb。同时,Dcn,Peg3,Sparc和Runx1,它们在静息软骨中高表达。增殖软骨细胞作为一类分化中间形态的细胞,它的注释比较复杂,增殖软骨生殖甚至与静息软骨相似的标记基因,如Ucma和Mest。我们也发现一些新的增殖软骨特异性的标记基因,包括Serpina3n和Wwp2。结合这些特异性的基因,能帮助我们更好的区分静息软骨和增殖软骨细胞。Prkg2,Alpl,Ihh,和Tgfbi作为前肥大软骨细胞的标记基因;Postn,Aspn,Lgals1,Ogn,Timp2和Ptn作为肥大软骨细胞的标记基因。WT小鼠和KO小鼠在这4类主要的软骨细胞中的分布和比例并没有明显差别。提示了Tudor-SN蛋白可能通过调控软骨细胞的基因表达,进而影响软骨内成骨过程。.为了进一步探讨Tudor-SN在软骨内成骨的作用,我们分析了在生长板软骨的各个细胞群中受Tudor-SN调控的基因。我们发现一系列与含有胶原细胞外基质相关的基因有明显差异,尤其是在preHTCs中。与钙离子应答相关的基因也有明显的改变,尤其是在RCs和ProCs中。在KO的软骨细胞中,与血管生成相关的基因很多基因的表达有所下降,比如Erg和Rhob。此外,在软骨细胞中特异性敲除Tudor-SN的小鼠也展现出成骨不全的表型,这进一步证明了Tudor-SN调控了软骨内成骨过程。这些结果表明Tudor-SN的确实会引起软骨内成骨相关基因的表达失调,从而导致了异常的骨骼延伸和骨小梁形成。我们的研究完善多能干细胞定向分化的精度和效力提供了有价值的见解,为成骨不全的发病机制提供理论依据。
RNA:m5C定点修饰工具开发
-
批准号:22377091
-
项目类别:面上项目
-
资助金额:46万元
-
批准年份:2023
-
负责人:杨洁
-
依托单位:
探讨Tudor-SN蛋白特异性调控胚胎中胚层分化的分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:54万元
-
批准年份:2022
-
负责人:杨洁
-
依托单位:
肿瘤蛋白SND1阻挠肿瘤细胞中MHC-I类分子抗原呈递导致肿瘤免疫逃逸的分子机制
-
批准号:31870747
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:杨洁
-
依托单位:
Rab25抑制非小细胞肺癌细胞自噬的机制研究
-
批准号:81702245
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:杨洁
-
依托单位:
Tudor-SN蛋白通过调控染色质的高级结构及周期阻滞促进DNA修复的机制
-
批准号:31670759
-
项目类别:面上项目
-
资助金额:65.0万元
-
批准年份:2016
-
负责人:杨洁
-
依托单位:
Tudor-SN蛋白调控细胞周期的分子机制研究
-
批准号:31370749
-
项目类别:面上项目
-
资助金额:90.0万元
-
批准年份:2013
-
负责人:杨洁
-
依托单位:
研究组蛋白或非组蛋白乙酰化修饰调控IL-4/STAT6信号传导通路基因转录活性的分子机制
-
批准号:90919032
-
项目类别:重大研究计划
-
资助金额:60.0万元
-
批准年份:2009
-
负责人:杨洁
-
依托单位:
多功能蛋白PSF抑制IL-4/STAT6转录活性的分子机制
-
批准号:30970582
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2009
-
负责人:杨洁
-
依托单位:
转录激活因子-人类p100蛋白参与pre-mRNA剪接加工分子机制的研究
-
批准号:30670441
-
项目类别:面上项目
-
资助金额:27.0万元
-
批准年份:2006
-
负责人:杨洁
-
依托单位:
有关STAT6信号传导通路及如何调控基因转录活性的分子机制的研究
-
批准号:30300070
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2003
-
负责人:杨洁
-
依托单位:
国内基金
海外基金